Why the study?
Cardiovascular diseases remain a major cause of death, and the application of exosomes as biomarkers and therapeutic delivery agents across different cardiovascular diseases is not yet mature.
Exosomes show potential as novel biomarkers and therapeutic delivery vehicles for various cardiovascular diseases, but further research is needed before clinical application.
Exosome applications in CVD remain exploratory; leaves open biomarker or therapeutic roles pending higher-level evidence.
Microvesicles known as exosomes have a diameter of 40 to 160 nm and are derived from small endosomal membranes. Exosomes have attracted increasing attention over the past ten years in part because they are functional vehicles that can deliver a variety of lipids, proteins, and nucleic acids to the target cells they encounter. Because of this function, exosomes may be used for the diagnosis, prognosis and treatment of many diseases. All throughout the world, cardiovascular diseases (CVDs) continue to be a significant cause of death. Because exosomes are mediators of communication between cells, which contribute to many physiological and pathological aspects, they may aid in improving CVD therapies as biomarkers for diagnosing and predicting CVDs. Many studies demonstrated that exosomes are associated with CVDs, such as coronary artery disease, heart failure, cardiomyopathy and atrial fibrillation. Exosomes participate in the progression or inhibition of these diseases mainly through the contents they deliver. However, the application of exosomes in diferent CVDs is not very mature. So further research is needed in this field.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: